Although considerable research has addressed the potential role of inflammatory mediators in the pathogenesis of coronary heart disease, the relevance of this pathway to the pathogenesis of type 2 diabetes has only recently attracted interest. Circulating levels of inflammatory mediators correlate with insulin resistance and are significantly elevated in groups at risk of type 2 diabetes. Several prospective studies indicate that C-reactive protein and white cell count, together with other acute phase markers, predict incident diabetes independently of established predictors. Measures known to prevent diabetes (weight loss, exercise and metformin) and those more recently suggested (statins, ACE inhibitors and thiazolidinediones) have all been shown to exhibit anti-inflammatory actions. Mechanisms linking inflammation to diabetes development are beginning to be unravelled. Emerging knowledge of inflammatory mediators may help to predict those at risk of type 2 diabetes, and further work in this area may lead to novel means of prevention and treatment.
Libby P., Ridker PM, Maseri A.Inflammation and atherosclerosis. Circulation2002;105:1135-43.
2.
Rifai N., Ridker PMProposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem2001 ;47:28-30.
3.
Rothkrantz-Kos S., Schmitz MP, Bekers O., Menheere PP, van Dieijen-Visser MPHigh-sensitivity C-reactive protein methods examined. Clin Chem2002;48:359-62.
4.
Veselka J., Prochazkova S., Duchonova R. et al. Relationship of C-reactive protein to presence and severity of coronary atherosclerosis in patients with stable angina pectoris or a pathological exercise test. Coron Artery Dis2002;13:151-4.
5.
Hill AG, Hill GLMetabolic response to severe injury. Br J Surg1998;85: 884-90.
6.
Mendall MA, Patel P., Ballam L., Strachan D., Northfield TCC reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ1996;312:1061-5.
7.
Pickup JC, Crook MAIs type II diabetes mellitus a disease of the innate immune system?Diabetologia1998;41:1241-8.
8.
Wallace AM, McMahon AD, Packard CJ, Shepherd J., Gaw A., Sattar N.Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study. Circulation2001 ;104:3052-6.
9.
Cook DG, Mendall MA, Whincup PH et al. C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. Atherosclerosis2000;149:139-50.
10.
Kelly CCJ , Lyall H., Petrie JR, Gould GW, Connell JMC , Sattar N.Low-grade Chronic Inflammation in Women with PCOS. J Clin Endocrinol Metab2001;86:2453-5.
11.
Forouhi NG, Sattar N., McKeigue P.Relation of C-reactive protein to cardiovascular risk factors in Europeans and South Asians. Int J Obesity2001;25:1327-31.
12.
Chambers JC , Eda S., Bassett P. et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation2001; 104:145-50.
13.
Weyer C., Yudkin JS, Stehouwer CD, Schalkwijk CG, Pratley RE, Tataranni PAHumoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis2002;161:233-42.
14.
Pannacciulli N., De Pergola G., Giorgino F., Giorgino R.A family history of Type 2 diabetes is associated with increased plasma levels of C-reactive protein in non-smoking healthy adult women. Diabet Med2002;19:689-92.
15.
Wannamethee SG, Lowe GD, Whincup PH, Rumley A., Walker M., Lennon L.Physical activity and hemostatic and inflammatory variables in elderly men. Circulation2002 ;105:1785-90.
16.
Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SWC-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?Arterioscler Thromb Vasc Biol1999;19:972-8.
17.
Festa A., D'Agostino R. Jr, Howard G., Mykkanen L., Tracy RP, Haffner SMChronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation2000;102:42-7.
18.
Schmidt MI, Duncan BB, Sharrett AR et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet1999;353:1649-52.
19.
Nakanishi N. , Yoshida H., Matsuo Y., Suzuki K., Tatara K.White blood-cell count and the risk of impaired fasting glucose or Type II diabetes in middle-aged Japanese men. Diabetologia2002;45:42-8.
20.
Vozarova B. , Weyer C., Lindsay RS, Pratley RE, Bogardus C., Tataranni PAHigh white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes2002;51:455-61.
21.
Pradhan AD, Manson JE, Rifai N., Buring JE, Ridker PMC-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA2001;286:327-34.
22.
Barzilay JI , Abraham L., Heckbert SR et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes2001;50:2384-9.
23.
Freeman DJ, Norrie J., Caslake M. et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study . Diabetes2002;51:1596-600.
24.
Festa A., D'Agostino R. Jr, Tracy RP, Haffner SMThe Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes2002;51: 1131-7.
25.
Lindsay RS, Funahashi T., Hanson RL et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet2002;360:57-8.
26.
Temelkova-Kurktschiev T., Siegert G., Bergmann S. et al. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism2002 ;51: 743-9.
27.
Mohamed-Ali V. , Pinkney JH, Coppack SWAdipose tissue as an endocrine and paracrine organ. Int J Obes1998;22:1145-58.
28.
Hotamisligil GS, Shargill NS, Spiegelman BMAdipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance . Science1993;259:87-91.
29.
Ofei F., Hurel S., Newkirk J., Sopwith M., Taylor R.Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes1996;45:881-5.
30.
Paquot N., Castillo MJ, Lefebvre PJ, Scheen AJNo increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab2000;85:1316-19.
31.
Bastard JP, Jardel C., Bruckert E. et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab2000;85:3338-42.
32.
Dovio A., Angeli A.Cytokines and type 2 diabetes mellitus. JAMA2001;286:2233.
33.
Khovidhunkit W., Memon RA, Feingold KR, Grunfeld C.Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis2000 ;181(suppl 3):S462-72.
34.
Björntorp P.Fatty acids, hyperinsulinemia, and insulin resistance: which comes first?Curr Opin Lipidol1994;5:166-74.
35.
Steinberg HO , Baron AD, Steinberg H. et al.: Vascular function, insulin resistance and fatty acids. Diabetologia2002;45:623-34.
36.
Vallance P. , Collier J., Bhagat K.Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link?Lancet1997;349: 1391-2.
37.
Cleland SJ, Sattar N., Petrie JR, Forouhi NG, Elliot H., McConnell JMC.Sensitive C-reactive protein and basal endothelial function. Clinical Science2000;98:531-35.
38.
van Exel E. , Gussekloo J., de Craen AJ et al. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes2002;51:1088-92.
39.
Gunnett CA, Heistad DD, Faraci FMInterleukin-10 protects nitric oxide-dependent relaxation during diabetes: role of superoxide. Diabetes2002; 51:1931-7.
40.
Walder K., Kantham L., McMillan JS et al. Tanis: a link between type 2 diabetes and inflammation?Diabetes2002;51:1859-66.
41.
Kim JK, Kim YJ, Fillmore JJ et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest2001;108:437-46.
42.
Yang WS, Lee WJ, Funahashi T. et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab2001;86:3815-19.
43.
Hotta K., Funahashi T., Bodkin NL et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes2001;50:1126-33.
44.
Knowler WC, Barrett-Connor E., Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med2002 ;346:393-403.
45.
Tuomilehto J., Lindström J., Erickson JG et al., for the Finnish Diabetes Prevention Study Group.Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Eng J Med2001;344:1343-50.
46.
Freeman DJ, Norrie J., Sattar N. et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation2001;103:357-62.
47.
Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G.Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med2000;342:145-53.
48.
Hansson L., Lindholm LH, Niskanen L. et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet1999;353:611-16.
49.
Tchernof A. , Nolan A., Sites CK, Ades PA, Poehlman ETWeight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation2002;105:564-9.
50.
Ridker PM, Rifai N., Pfeffer MA, Sacks F., Braunwald E.Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation1999; 100:230-5.
51.
Gullestad L. , Aukrust P., Ueland T. et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol1999;34:2061-7.
52.
Haffner SM, Greenberg AS, Weston WM, Chen H., Williams K., Freed MIEffect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation2002; 106:679-84.
